[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537257":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":45,"collaborators":20,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":20,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"University Hospital, Brest","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ga68-FAPI46 TEP scan","EXPERIMENTAL","In addition to the usual routine care, the study adds the performance of a \\[68Ga\\] Ga-FAPI PET\u002FCT scan",[13],"Diagnostic Test: 68Ga-FAPI46",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","68Ga-FAPI46","Depending on the situation, it is planned that this evaluation will be transversal (performing \\[68Ga\\] Ga-FAPI PET\u002FCT at baseline) or longitudinal (performing \\[68Ga\\] Ga-FAPI PET\u002FCT at baseline and at 3\u002F6 months for patients benefiting from an intensification of therapeutic management at inclusion).",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Pierre-Yves LE ROUX, PHD","CONTACT","+33 (0) 229020266","pierre-yves.leroux@chu-brest.fr",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Chu Brest","RECRUITING","Brest","29200","France","FR",{"type":36,"coordinates":37},"Point",[38,39],-4.48628,48.39029,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":26},"Pierre-Yves LE ROUX, PU-PH","+33229020266",{"type":46,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100537257","68gallium-fapi46-petct-imaging-in-chronic-inflammatory-and-fibrotic-diseases-100537257",false,"NCT06275477","68Gallium-FAPI46 PET\u002FCT Imaging in Chronic Inflammatory and Fibrotic Diseases","PARADISE","Inclusion Criteria:\n\n* Patient aged 18 or over.\n* Affected by one of the pathologies concerned by the study (see Table 4)\n* Satisfying the consensus classification criteria for the pathology (Table 3).\n* Satisfying the corresponding clinical situation (Table 3).\n* Negative urine pregnancy test for women of childbearing age.\n* Affiliated with or benefiting from social security.\n* Informed consent (personally dated and) signed by the participant or any representatives (impartial witness\u002Ftrusted person).\n\nExclusion Criteria:\n\n* Patients unable to consent.\n* Incapacitated adults.\n* Pregnant or breastfeeding women.\n* Patients refusing to participate in research.\n* Known active cancer.\n* Women of childbearing potential unwilling to use appropriate contraception (definitions given in Annex 1).","ALL","18 Years",{"count":57,"type":58},390,"ESTIMATED","INTERVENTIONAL",[61],"NA","This single-center pilot study is designed to explore the preliminary utility of the \\[68Ga\\] Ga-FAPI imaging agent in positron emission tomography (PET) combined with computed tomography (CT) for a range of chronic inflammatory and fibrosing diseases. The study focuses on the potential of \\[68Ga\\] Ga-FAPI, a novel radiotracer targeting Fibroblast Activation Protein (FAP), to improve diagnostic accuracy in various medical conditions. Thirteen distinct clinical situations have been selected for this investigation, including rheumatoid arthritis, liver fibrosis, and systemic lupus, among others. This approach aims to ascertain the value of further clinical development in each area and refine the use of this imaging modality in routine care for both initial evaluation and ongoing monitoring of these diseases.",[64],"Inflammatory Disease","2026-06-15",{"date":67,"type":68},"2026-06-16","ACTUAL",{"date":70,"type":68},"2025-03-13",{"date":72,"type":58},"2028-10-05",{"name":5,"class":6},1]